PHARMACEUTICAL 2023

Maravai Lifesciences Holdings INC
Rank 246 of 471



PHARMACEUTICAL 2023

Maravai Lifesciences Holdings INC
Rank 246 of 471

The relative strengths and weaknesses of Maravai Lifesciences Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Maravai Lifesciences Holdings INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 76% points.The greatest weakness of Maravai Lifesciences Holdings INC is the variable Liabilities, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 251%, being 6.4% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	847,902
Cost of Goods Sold	168,957
Intangible Assets	500,331
Liabilities, Current	110,144
Liabilities, Non-Current	590,972
Other Assets	881,388
Other Compr. Net Income	-270,458
Other Expenses	77,525
Other Liabilities	675,956
Other Net Income	1,772
Other Revenues	883,001
Property and Equipment	52,694
Research and Development	18,369
Selling, General and Administrative Expense	129,259

Output Variable	Value in 1000 USD
Assets	2,282,315
Liabilities	1,377,072
Expenses	394,110
Revenues	883,001
Stockholders Equity	905,243
Net Income	490,663
Comprehensive Net Income	355,434
BaseVar	2,604,364
ECR before LimitedLiability	127%
Economic Capital Ratio	251%